Uromedica

Executive Summary

Uromedica is a privately held medical device company focused on urology, specifically stress urinary incontinence (SUI). Its core product, the Adjustable Continence Therapy (ACT) system, is a minimally invasive, long-term implantable balloon therapy for SUI in men (ProACT) and women (ACT). The system offers a unique adjustable mechanism that differentiates it from static slings or artificial urinary sphincters. While the ACT system is commercialized in over 30 countries, it remains investigational in the United States, pending FDA approval. The company has been operational since 1996 and has amassed a substantial body of clinical evidence supporting safety and efficacy. However, as a small private entity, Uromedica faces challenges in scaling commercialization and navigating the stringent FDA regulatory pathway. The value proposition lies in its potential to address an unmet need for patients who fail conservative management or are not candidates for more invasive surgeries. Key risks include regulatory hurdles, competition from established SUI treatments, and limited financial resources to fund a US pivotal trial.

Upcoming Catalysts (preview)

• Q4 2026FDA Investigational Device Exemption (IDE) approval for US pivotal trial50% success
• Q2 2027Publication of long-term clinical data from European registry70% success
• TBDStrategic partnership or licensing deal for US commercialization40% success